Bgm (BGM) Total Current Liabilities (2019 - 2025)
Bgm's (BGM) quarterly Total Current Liabilities came in at $41.6 million in Q3 2025, up 373.99% year-on-year from $8.8 million in Q3 2024, and up 76.37% on a QoQ basis from $23.6 million in Q1 2025.
Bgm (BGM) Total Current Liabilities (2019 - 2025) Analysis & Trends
Bgm (BGM) has 7 years of Total Current Liabilities data on file, last reported at $41.6 million in Q3 2025.
- On a quarterly basis, Total Current Liabilities rose 373.99% year-over-year to $41.6 million in Q3 2025; TTM through Sep 2025 was $41.6 million, a 373.99% increase from a year earlier, with the FY2025 full-year figure at $41.6 million, up 373.99% from the prior year.
- Total Current Liabilities for Q3 2025 stood at $41.6 million, up from $23.6 million in the prior quarter.
- Over the last five years, Total Current Liabilities for BGM reached as high as $22174.7 billion in Q1 2022 and fell as low as $4.7 million in Q1 2024.
- Historically, Total Current Liabilities has averaged $3484.2 billion across 5 years, with a median of $18.2 million in 2021.
- Across the five-year window, Total Current Liabilities tumbled 100.0% in 2024 and soared 398.71% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $18.2 million in 2021, then plunged by 49.49% to $9.2 million in 2022, then fell by 27.45% to $6.7 million in 2023, then soared by 31.77% to $8.8 million in 2024, then surged by 373.99% to $41.6 million in 2025.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $41.6 million in Q3 2025, $23.6 million in Q1 2025, and $8.8 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 599.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 19.22 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Bgm | 33.55 Mn | 23.73 Mn | - | 41.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 41.60 Mn |
| Mar 31, 2025 | 23.59 Mn |
| Sep 30, 2024 | 8.78 Mn |
| Mar 31, 2024 | 4.73 Mn |
| Sep 30, 2023 | 6.66 Mn |
| Mar 31, 2023 | 9,183.23 Bn |
| Sep 30, 2022 | 9.18 Mn |
| Mar 31, 2022 | 22,174.68 Bn |
| Sep 30, 2021 | 18.17 Mn |
| Sep 30, 2020 | 18.42 Mn |
| Sep 30, 2019 | 11.66 Mn |